QT Interval Shortening With Isavuconazole:In VitroandIn VivoEffects on Cardiac Repolarization
Authors:
Open Access
- 11 January 2017
- journal article
- research article
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 101 (6) , 782-790
Abstract
The effects of isavuconazole (active moiety of isavuconazonium sulfate) on cardiac ion channelsin vitroand cardiac repolarization clinically were assessed in a phase I, randomized, double‐blind study in healthy individuals who received isavuconazole (after 2‐day loading dose), at therapeutic or supratherapeutic doses daily for 11 days, moxifloxacin (400 mg q.d.), or placebo. A post‐hoc analysis of the phase III SECURE trial assessed effects on cardiac safety. L‐type Ca2+channels were most sensitive to inhibition by isavuconazole. The 50% inhibitory concentrations for ion channels were higher than maximum serum concentrations of nonprotein‐bound isavuconazolein vivo. In the phase I study (n = 161), isavuconazole shortened the QT interval in a dose‐ and plasma concentration‐related manner. There were no serious treatment‐emergent adverse events; palpitations and tachycardia were observed in placebo and supratherapeutic isavuconazole groups; no cardiac safety signals were detected in the SECURE study (n = 257). Isavuconazole was associated with a shortened cardiac QT interval.Keywords
This publication has 28 references indexed in Scilit:
- Profile of isavuconazole and its potential in the treatment of severe invasive fungal infectionsInfection and Drug Resistance, 2013
- Drug-induced QT-interval shortening following antiepileptic treatment with oral rufinamideHeart Rhythm, 2012
- Drug-Induced Long QT SyndromePharmacological Reviews, 2010
- Drug‐induced QT interval shortening: potential harbinger of proarrhythmia and regulatory perspectivesBritish Journal of Pharmacology, 2010
- Lamotrigine does not prolong QTc in a thorough QT/QTc study in healthy subjectsBritish Journal of Clinical Pharmacology, 2008
- Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus GroupClinical Infectious Diseases, 2008
- Antimicrobial-Associated QT Interval Prolongation: Pointes of InterestClinical Infectious Diseases, 2006
- Distribution and Prognostic Significance of QT Intervals in the Lowest Half Centile in 12,012 Apparently Healthy PersonsThe American Journal of Cardiology, 2006
- Mechanism of hERG K+channel blockade by the fluoroquinolone antibiotic moxifloxacinBritish Journal of Pharmacology, 2006
- Voriconazole-Induced QT Interval Prolongation and Ventricular Tachycardia: A Non--Concentration-Dependent Adverse EffectClinical Infectious Diseases, 2004